期刊
EXPERT REVIEW OF VACCINES
卷 5, 期 4, 页码 417-430出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.5.4.417
关键词
anthrax; anthrax vaccine; Bacillus anthracis; immunization; recombinant protective antigen
类别
Recent terrorist attacks involving the use of Bacillus onthrocis spores have stimulated interest in the development of new vaccines for anthrax prevention. Studies of the pathogenesis of anthrax and of the immune responses following infection and immunization underscore the pivotal role that antibodies to the protective antigen play in protection. The most promising vaccine candidates contain purified recombinant protective antigen. Clinical trials of one of these, recombinant protective antigen (rPA)102, are underway. Initial results suggest that rPA102 is well tollerated and immunogenic. Additional trials are necessary to identity optimal formulations and immunization regimens for pre- and postexposure prophylaxis. Future licensure of these and other candidate vaccines will depend on their safety and immunogenicity profiles in humans, and their ability to confer protection in animal models of inhalational anthrax.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据